Templeton Emerging Markets Investment Trust PLC ('TEMIT')
On behalf of TEMIT, Franklin Templeton Investment Trust Management Limited reports the unaudited cum-income net asset value ('NAV') of TEMIT as at
02 May 2025 was £1983.160m, representing a NAV of 194.47 pence per share.
The unaudited ex-income NAV of TEMIT as at 02 May 2025 was £1938.390m, representing a NAV of 190.08 pence per share.
In accordance with the Association of Investment Companies recommendations, the cum-income NAV has been calculated based on the total value of underlying assets,
including accumulated or accrued income, and using bid price information relating to the underlying assets.
The ex-income NAV has been calculated based on the total value of underlying assets, excluding these income elements, and using bid price information relating to the underlying assets.
Portfolio data for TEMIT can be found on the website www.TEMIT.co.uk.
For information please contact Client Dealer Services on freephone 0800 305 306.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
Osmium pair pulls plug on board push.
Cash earnings were flat, and net interest margin rose slightly.
The pharmaceutical firm is pushing for approval of multiple phase-three trials in 2026.
To join your company account for BusinessDesk and enjoy full access, enter your email and we’ll send you details